Results 31 to 40 of about 12,817 (217)

Mutations in E2-PePHD, NS5A-PKRBD, NS5A-ISDR, and NS5A-V3 of Hepatitis C Virus Genotype 1 and Their Relationships to Pegylated Interferon-Ribavirin Treatment Responses [PDF]

Journal of Virology, 2008
ABSTRACTMutations in several subgenomic regions of hepatitis C virus (HCV) have been implicated in influencing the response to interferon (IFN) therapy. Sequences within HCV NS5A (PKR binding domain [PKRBD], IFN sensitivity-determining region [ISDR], and variable region 3 [V3]) were analyzed for the pretreatment serum samples of 60 HCV genotype 1 ...
P, Muñoz de Rueda, J, Casado, R, Patón, D, Quintero, A, Palacios, A, Gila, R, Quiles, J, León, A, Ruiz-Extremera, J, Salmerón   +9 more
openaire   +2 more sources

A new method of producing NS5A antigen of hepatitis C virus

Вопросы вирусологии, 2017
A task of creating a universal platform for engineering affordable recombinant producers of viral proteins conserving immunogenicity has not been solved yet.
T. V. Kuznetsova, M. S. Smirnova, O. A. Leonovich, I. V. Gordeichuk, I. K. Biriukova, M. V. Zylkova, Ya. Ya. Tyn’O, A. V. Belyakova, A. B. Shevelev   +8 more
doaj   +1 more source

Identification of Hepatitis C Virus NS5A Inhibitors [PDF]

Journal of Virology, 2010
ABSTRACT Using a cell-based replicon screen, we identified a class of compounds with a thiazolidinone core structure as inhibitors of hepatitis C virus (HCV) replication. The concentration of one such compound, BMS-824, that resulted in a 50% inhibition of HCV replicon replication was ∼5 nM, with a therapeutic index of >10,000. The
Julie A, Lemm, Donald, O'Boyle, Mengping, Liu, Peter T, Nower, Richard, Colonno, Milind S, Deshpande, Lawrence B, Snyder, Scott W, Martin, Denis R, St Laurent, Michael H, Serrano-Wu, Jeffrey L, Romine, Nicholas A, Meanwell, Min, Gao   +12 more
openaire   +2 more sources

Cyclosporine inhibits a direct interaction between cyclophilins and hepatitis C NS5A.

PLoS ONE, 2010
BackgroundHepatitis C Virus (HCV) infection is a leading indication for liver transplantation. HCV infection reoccurs almost universally post transplant, decreasing both graft longevity and patient survival.
Fiona Fernandes, Israr-ul H Ansari, Rob Striker   +2 more
doaj   +1 more source

Analysis of functional differences between hepatitis C virus NS5A of genotypes 1-7 in infectious cell culture systems.

PLoS Pathogens, 2012
Hepatitis C virus (HCV) is an important cause of chronic liver disease. Several highly diverse HCV genotypes exist with potential key functional differences.
Troels K H Scheel, Jannick Prentoe, Thomas H R Carlsen, Lotte S Mikkelsen, Judith M Gottwein, Jens Bukh   +5 more
doaj   +1 more source

Retreatment of patients with chronic hepatitis C, subtype 3a, and cirrhosis, who previously failed a regimen containing NS5A inhibitors with sofosbuvir/velpatasvir plus ribavirin for 24 weeks

Journal of Clinical Virology Plus, 2023
Background & Aims The use of direct acting antiviral agents (DAAs) in patients with chronic HCV genotype (GT) 3a infection results in sustained virologic response (SVR) rates of 93–98%, but 5–8% of patients experience virologic failure. Methods.
Sergii V. Fedorchenko, Tatiana Martynovych, Zhanna Klimenko, Iryna Solianyk   +3 more
doaj   +1 more source

NMR and circular dichroism data for domain 2 of the HCV NS5A protein phosphorylated by the Casein Kinase II

Data in Brief, 2018
The Hepatitis C Virus (HCV)11 HCV: Hepatitis C Virus; HSQC: heteronuclear single-quantum coherence; NS5A: nonstructural protein 5A; NS5A-D2: domain 2 of the nonstructural protein 5A; CKII: Casein kinase II, NS5A-D2_CKII: NS5A-D2 phosphorylated by CKII ...
Luiza M. Bessa, Robert Schneider, Xavier Hanoulle   +2 more
doaj   +1 more source

Analysis of genetic polymorphisms and drug resistance mutations in the NS5 region of HCV genome (Flasuviricetes: Amarillovirales: Flaviviridae: Hepacivirus C) in samples obtained in 2022–2023 from HIV-infected treatment-naive residents of Altai Krai

Вопросы вирусологии
Introduction. Altai Krai is a region with an unfavorable situation of HIV-1 and HCV infection, as well as HIV-1 and HCV coinfection. Due to this, it is necessary to study the HCV genetic variants and their drug resistance (DR) to direct-acting antivirals
Ilya A. Lapovok, Arina V. Syrkina, Alina A. Kirichenko, Anastasia V. Shlykova, Natalya V. Lukyanenko, Tatyana V. Safyanova, Arina E. Safronova, Valery V. Shevchenko, Dmitry E. Kireev   +8 more
doaj   +1 more source

Subtype-Specific Prevalence of Hepatitis C Virus NS5A Resistance Associated Substitutions in Mainland China

Frontiers in Microbiology, 2019
Resistance associated substitutions (RASs) can reduce the efficacy of direct-acting antiviral agents (DAAs) targeting hepatitis C virus (HCV) and lead to treatment failure.
Jie Lu, Yupeng Feng, Lichang Chen, Zhengyu Zeng, Xianliang Liu, Wei Cai, Hui Wang, Xiaolei Guo, Huijuan Zhou, Wanyin Tao, Qing Xie   +10 more
doaj   +1 more source

HCV NS5A and IRF9 compete for CypA binding [PDF]

Journal of Hepatology, 2013
Cyclophilin A (CypA) is vital for HCV replication. Cyp inhibitors successfully decrease viral loads in HCV-infected patients. However, their mechanisms of action remain unknown. Since interferon (IFN) can also suppress HCV replication, we asked whether a link between CypA and the IFN response exists.We used cellular and recombinant pulldown approaches ...
Michael, Bobardt, Sam, Hopkins, James, Baugh, Udayan, Chatterji, Felicia, Hernandez, John, Hiscott, Ann, Sluder, Kai, Lin, Philippe A, Gallay   +8 more
openaire   +2 more sources